Ultragenyx Pharmaceutical Inc.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
RARE$16.14-1.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Equity (Deficit)
| Common Stock | AdditionalPaid-In | AccumulatedOtherComprehensive | Accumulated | Treasury | Deferred Compensation | TotalStockholders' | |
|---|---|---|---|---|---|---|---|
| Shares | Capital | Income (Loss) | Deficit | Stock | Obligation | Deficit | |
| Balance as of June 30, 2026 | 98.6 | $4,518 | $— | $(4,809) | $(10) | $10 | $(291) |
| Stock-based compensation | — | 34 | — | — | — | — | 34 |
| Issuance of common stock from warrant exercises and equity plan awards, net of tax | 3.3 | — | — | — | — | — | — |
| Other comprehensive loss | — | — | (1) | — | — | — | (1) |
| Net loss | — | — | — | (118) | — | — | (118) |
| Balance as of September 30, 2026 | 101.9 | $4,552 | $(1) | $(4,927) | $(10) | $10 | $(376) |
| Balance as of December 31, 2025 | 96.6 | $4,451 | $1 | $(4,532) | $(8) | $8 | $(80) |
|---|---|---|---|---|---|---|---|
| Stock-based compensation | — | 98 | — | — | — | — | 98 |
| Issuance of common stock from warrant exercises and equity plan awards, net of tax | 5.3 | 3 | — | — | — | — | 3 |
| Deferred compensation | — | — | — | — | (2) | 2 | — |
| Other comprehensive loss | — | — | (2) | — | — | — | (2) |
| Net loss | — | — | — | (395) | — | — | (395) |
| Balance as of September 30, 2026 | 101.9 | $4,552 | $(1) | $(4,927) | $(10) | $10 | $(376) |
| Common Stock | AdditionalPaid-In | AccumulatedOtherComprehensive | Accumulated | Treasury | Deferred Compensation | TotalStockholders' | |
|---|---|---|---|---|---|---|---|
| Shares | Capital | Income (Loss) | Deficit | Stock | Obligation | Equity | |
| Balance as of June 30, 2025 | 96.4 | $4,374 | $— | $(4,223) | $(8) | $8 | $151 |
| Stock-based compensation | — | 38 | — | — | — | — | 38 |
| Issuance of common stock under equity plan awards, net of tax | — | — | — | — | — | — | — |
| Other comprehensive income | — | — | 1 | — | — | — | 1 |
| Net loss | — | — | — | (180) | — | — | (180) |
| Balance as of September 30, 2025 | 96.4 | $4,412 | $1 | $(4,403) | $(8) | $8 | $10 |
| Balance as of December 31, 2024 | 92.5 | $4,213 | $(1) | $(3,957) | $(4) | $4 | $255 |
|---|---|---|---|---|---|---|---|
| Issuance of common stock in connection with at-the-market offering, net | 2.2 | 80 | 80 | ||||
| Stock-based compensation | — | 115 | — | — | — | — | 115 |
| Issuance of common stock under equity plan awards, net of tax | 1.7 | 4 | — | — | — | — | 4 |
| Deferred compensation | — | — | — | — | (4) | 4 | — |
| Other comprehensive income | — | — | 2 | — | — | — | 2 |
| Net loss | — | — | — | (446) | — | — | (446) |
| Balance as of September 30, 2025 | 96.4 | $4,412 | $1 | $(4,403) | $(8) | $8 | $10 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.